RIBOPRO secures Series A Funding to advance mRNA-based technologies
Oss, the Netherlands, 31 October 2024 — RIBOPRO, a prominent technology and service provider specialising in the development and production of mRNA and lipid nanoparticles, has successfully closed a Series A funding round.
This funding will drive efforts to transform the industry with innovative mRNA and LNP technologies, providing a range of solutions to address current challenges within the field. These include an advanced and flexible mRNA/LNP manufacturing platform, which equips the healthcare sector to prepare for future pandemics and offers the capability to produce personalised cancer therapies in a responsive and cost-effective manner.
Since its founding in 2020, RIBOPRO has rapidly established itself as an influential player in the mRNA sector. The company has developed several patented design and process technologies, ensuring highly functional mRNA products for a global client base. The new funding will support the scaling of operations, further technological development, and enhanced marketing and sales initiatives.
Read the full press release here.
Find more news here.